Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) is expected to release its earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last posted its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Telomir Pharmaceuticals Stock Performance
TELO opened at $2.59 on Monday. The company has a market cap of $77.09 million, a PE ratio of -4.47 and a beta of 0.17. The stock has a 50-day moving average of $3.41 and a 200-day moving average of $4.14. Telomir Pharmaceuticals has a 52-week low of $2.35 and a 52-week high of $8.40.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on TELO. Rodman & Renshaw began coverage on Telomir Pharmaceuticals in a research report on Friday, February 21st. They set a "buy" rating and a $15.00 target price for the company. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a "strong-buy" rating in a report on Thursday, February 20th.
Check Out Our Latest Stock Report on TELO
Hedge Funds Weigh In On Telomir Pharmaceuticals
An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE boosted its holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 283.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,713 shares of the company's stock after buying an additional 10,880 shares during the period. Bank of America Corp DE's holdings in Telomir Pharmaceuticals were worth $61,000 as of its most recent SEC filing.
Telomir Pharmaceuticals Company Profile
(
Get Free Report)
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telomir Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list.
While Telomir Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
